Immunome Initiated at Overweight by Barclays
Barclays Initiates Immunome at Overweight
Barclays has initiated coverage on Immunome (IMNM) with an Overweight rating and a price target of $36.00 per share. This development signals a positive outlook for the biotechnology company.
Price Target and Assessment
Analysts highlight significant upside potential compared to Immunome's current market valuation. The Barclays report is based on the company's drug development pipeline and market opportunities.
Investors are closely watching IMNM shares following this news. The initiation note is seen as a positive catalyst for the stock.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…